Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Yinghong Zhai, Fangyuan Hu, Wentao Shi, Xiaofei Ye, Jingfang Xu, Xiaojing Guo, Yang Cao, Jia He & Feng Xu. (2023) Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors. Expert Opinion on Drug Safety 22:9, pages 857-869.
Read now
Read now
Chenxin Chen, Xiaoyong Miao, Xiaojing Guo, Jinfang Xu, Jizhou Liang, Yi Zheng, Lijie Chi, Xiao Chen, Lianhui Wei, Hewei Zhang, Xiaofei Ye & Jia He. (2023) Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase). Expert Opinion on Drug Safety 0:0, pages 1-9.
Read now
Read now
Zhiping Li, Wenbin Zou, Jiao Yuan, Yunxiang Zhong & Zhiwen Fu. (2023) Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system. Expert Opinion on Drug Safety 0:0, pages 1-8.
Read now
Read now
Nayoung Han, Jung Mi Oh & In-Wha Kim. (2021) Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems. Therapeutics and Clinical Risk Management 17, pages 877-887.
Read now
Read now
Nitish Aggarwal. (2018) Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation. Expert Opinion on Drug Safety 17:6, pages 581-587.
Read now
Read now
Articles from other publishers (24)
Haining Huang, Lanfang Li, Mingli Wu, Zhen Liu, Yanyan Zhao, Jing Peng, Xiaolei Ren & Shuai Chen. (2023) Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022. BMC Pharmacology and Toxicology 24:1.
Crossref
Crossref
Ying Zhang, Li Ran, Yongchao Liang, Yanqiu Zhang & Zhuoling An. (2023) Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system. Frontiers in Pharmacology 14.
Crossref
Crossref
Yanfeng Wang, Chanjuan Cui, Lei Deng, Lin Wang & Xiayang Ren. (2023) Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022. Frontiers in Immunology 14.
Crossref
Crossref
Xiuxian Lin, Jianhui Yang, Lizhu Weng & Wanlong Lin. (2023) Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. The Journal of Allergy and Clinical Immunology: In Practice 11:5, pages 1494-1502.e6.
Crossref
Crossref
Yinghong Zhai, Fangyuan Hu, Borui Zhu, Jinfang Xu, Xiaojing Guo, Wentao Shi, Xiang Zhou, Yi Zheng, Xiao Xu, Xiaofei Ye, Jia He & Feng Xu. (2023) Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study. Immunotherapy 15:6, pages 443-456.
Crossref
Crossref
Xiangli Cui, Cilin Yan, Ye Xu, Dandan Li, Mingxing Guo, Liying Sun & Zhijun Zhu. (2022) Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system. Cancer Medicine 12:5, pages 5181-5194.
Crossref
Crossref
Zhiqiang Song, Dingyuan Tu, Gusheng Tang, Na Liu, Zongguang Tai, Jianmin Yang & Yang Wang. (2023) Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy. Haematologica 108:8, pages 2067-2079.
Crossref
Crossref
Hui Zhao, Zi-Ran Li, Qian Zhang, Ming-Kang Zhong, Ming-Ming Yan & Xiao-Yan Qiu. (2023) Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database. Frontiers in Pharmacology 14.
Crossref
Crossref
Qiang Lyu, Pei Ye, Hewei Zhang, Xiaofei Ye, Yi Zheng, Jinfang Xu, Xiao Chen, Chenxin Chen & Xiaojing Guo. (2022) Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database. British Journal of Clinical Pharmacology 89:2, pages 449-457.
Crossref
Crossref
Tianqi Gu, Aimin Jiang, Chaozheng Zhou, Anqi Lin, Quan Cheng, Zaoqu Liu, Jian Zhang & Peng Luo. (2022) Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. International Journal of Cancer 152:3, pages 480-495.
Crossref
Crossref
Shichao Dong & Chuan Sun. (2022) Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Frontiers in Endocrinology 13.
Crossref
Crossref
YanFeng Wang, Chanjuan Cui, Xiayang Ren, Xinran Dong & Wei Cui. (2022) Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Hyeon Tae Park, Sunny Park, Yong Woo Jung & Soo An Choi. (2022) Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database. Diagnostics 12:10, pages 2434.
Crossref
Crossref
K. Ouoba, H. Lehmann, J.-Y. Pabst & R. Semde. (2022) Revue de la littérature sur la pharmacovigilance des médicaments issus des pharmacopées traditionnelles. Partie II : évaluation et prévention des risques. Annales Pharmaceutiques Françaises 80:5, pages 635-645.
Crossref
Crossref
Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Zhen Lin, Xiang Zhou, Zhijian Guo, Yang Cao & Jia He. (2022) Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Xiang Zhou, Yi Zheng, Xinxin Zhao, Xiao Xu, Yang Cao & Jia He. (2022) Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study. Frontiers in Endocrinology 12.
Crossref
Crossref
Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yang Cao, Zhen Lin, Xiang Zhou, Zhijian Guo & Jia He. (2021) Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Yu-ming Guo, Fei-lin Ge, Hai-bo Song, Peng Xiong, Jing Jing, Ming Niu, Xu Zhao, Zhao-fang Bai, Jia-bo Wang & Xiao-he Xiao. (2021) Relative Risk Analysis of Liver-related Adverse Drug Reactions in Children Based on China’s National Spontaneous Reporting System. The Journal of Pediatrics 234, pages 85-91.
Crossref
Crossref
Chenxin Chen, Ting Chen, Jizhou Liang, Xiaojing Guo, Jinfang Xu, Yi Zheng, Zhijian Guo, Lijie Chi, Lianhui Wei, Xiao Chen, Xiaofei Ye & Jia He. (2021) Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Frontiers in Pharmacology 12.
Crossref
Crossref
Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yonglong Zhuang & Jia He. (2019) Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Liping Tan, Mujin Li & Ying Lin. (2019) Safety Concerns of Traditional Chinese Medicine Injections Used in Chinese Children. Evidence-Based Complementary and Alternative Medicine 2019, pages 1-10.
Crossref
Crossref
Pushkar Aggarwal. (2019) Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis. Therapeutic Advances in Drug Safety 10, pages 204209861986907.
Crossref
Crossref
Tianyi Zhang, Xiaofei Ye, Xiaojing Guo, Guizhi Wu, Yongfang Hou, Jinfang Xu, Wentao Shi, Tiantian Zhu, Yuan Zhang, Xinji Zhang, Jiaqi Song & Jia He. (2017) Signal Detection Based on Time to Onset Algorithm in Spontaneous Reporting System of China. Drug Safety 40:4, pages 343-350.
Crossref
Crossref
Jing Wang, Xiao-Fei Ye, Xiao-Jing Guo, Tian-Tian Zhu, Na Qi, Yong-Fang Hou, Tian-Yi Zhang, Wen-Tao Shi, Xin Wei, Yu-Zhou Liu, Gui-Zhi Wu & Jia He. (2015) Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China. Pharmacoepidemiology and Drug Safety 24:9, pages 962-970.
Crossref
Crossref